Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia

INTRODUCTION: No head-to-head studies have compared inotuzumab ozogamicin (InO) and blinatumomab (Blina) for the treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL). Indirect treatment comparisons (ITCs), namely network meta-analysis (NMA), anchored ma...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Adv Ther
Päätekijät: Proskorovsky, Irina, Su, Yun, Fahrbach, Kyle, Vandendries, Erik, Pagé, Véronique, Onyekwere, Uchenna, Wang, Yunyang, Cappelleri, Joseph C., Stelljes, Matthias
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer Healthcare 2019
Aiheet:
Original Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6822860/
https://ncbi.nlm.nih.gov/pubmed/31140123
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-019-00991-w
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia